FDA OKs immunotherapy regimen for platinum-resistant ovarian cancer

Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)—in combo with paclitaxel—are the first PD-1 inhibitors approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma …